Abstract
The addition of new agents to the armamentarium of treatment options for heart failure in pediatric patients is exciting and challenging. Administration of these therapies to pediatric patients will require careful scrutiny of the data and skilled application. Developmental changes in drug metabolism, excretion, and distribution are concerning in pediatric patients, and inappropriate evaluation of these parameters can have disastrous results. Manipulation of the neurohormonal pathways in heart failure has been the target of most recently developed pharmacologic agents. Angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, and natriuretic peptides are seeing increased use in pediatrics. In particular, calcium sensitizing agents represent a new frontier in the treatment of acute decompensated heart failure and may replace traditional inotropic therapies. Endothelin receptor antagonists have shown benefit in the treatment of pulmonary hypertension, but their use in heart failure is still debatable. Vasopressin antagonists, tumor necrosis factor inhibitors, and neutral endopeptidase inhibitors are also targeting aspects of the neurohormonal cascade that are currently not completely understood. The future of pharmacologic therapies will include pharmacogenomic studies on new and preexisting therapies for pediatric heart failure. The education and skill of the practitioner when applying these agents in pediatric heart failure is of utmost importance.
Similar content being viewed by others
References
Anker SD, Coats AJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123–130
Antila S, Asko J, Honkanen T, Letonen L (2000) Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. Eur J Clin Pharmacol 56:705–710
Antila S, Eha J, Heinpalu M, et al. (1996) Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 49:451–458
Antila S, Honkanen T, Lehtonen L, Neuvonen PJ (1998) The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium sensitizing drug levosimendan. Int J Clin Pharmacol Ther 36:446–449
Antila S, Huuskohen H, Nevalainen T, et al. (1999) Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 9:85–91
Antila S, Jarvinen A, Akkila J, et al. (1997) Studies on psychomotoric effects and pharmacokinetic drug interactions of the new calcium sensitizing drug levosimendan and ethanol. Arnzneimittelforschung 47:816–820
Azeka E, Ramires JAF, Valler C, Bocchi EA (2002) Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 40:2034–2038
Berger R, Stanek B, Hulsmann M, et al. (2001) Effects of endothelin A receptor blockade on endothelin function in patients with chronic heart failure. Circulation 103:981–986
Boekstegers P, Wedenhofer S, Zell R, et al. (1994) Repeated administration of a F(ab’)2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1:237–245
Book WM, Hott BJ, McConnell M (2005) B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 95:545–546
Bosentan package insert (2003) Actelion Pharmaceuticals US South San Francisco,CA
Bozkurt B, Torre-Amione G, Warren M, et al. (2001) Results of targeted anti-tumor necrosis factor therapy with Etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:l044–1047
Braun JP, Schneider M, Dohmen P, Dopfmer U (2004) Succesful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J Cardiothorac Vasc Anesth 18:772–774
Braur JP, Schneider M, Kastrup M, Liu J (2004) Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 26:228–230
Brehm BR, Wolf SC, Bertsch D, et al. (2001) Effects of nebivolol on proliferation and apsoptosis on human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 49:430–439
Brehm BR, Wolf SC, Corner S, et al. (2002) Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 4:757–763
Brickner ME, Hillis LD, Lange RA (2000) Congenital heart disease in adults. N Engl J Med 342:252–263
Bristow MR (1997) Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80:26L–40L
Brouard R, Laporte V, Serradeil-Le Gal C, et al. (1998) Safety, tolerability, and pharmacokinetics of SR 49059, a VI a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv Exp Med Biol 449:455–465
Bruns LA, Chrisant MK, Lamour JM, et al. (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505–511
Burger AJ, Elkayam U, Neibaur M, et al. (2001) Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine vs. nesiritide therapy. Am J Cardiol 88:35–39
Burnier M (2000) Angiotensin II type I receptor blockers. Circulation 103:904–912
Burnier M, Fricker AF, Hayoz D, et al. (1999) Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55:633–637
Campbell H, Surry SAM, Royle EM (1998) A review of randomized controlled trial published in the Archives of Disease in Childhood from 1982–96. Arch Dis Child 79:192–197
Carson P, Ziesche S, Johnson G, et al. (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:178–187
Cascorbil, Gerloff T, Johne A, et al. (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174
Colucci WS, Elkayam U, Horton DP (2000) Intravenous nesritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med 343:246–253
Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. (2006) Vasopressin-2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273–F278
Cotter G, Kaluski E, Stangl K, et al. (2004) The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6:601–609
Crozier I, Ikram H, Awan N, et al. (1995) Losartan in heart failure: hemodynamic effects and tolerability. Circulation 91:691–697
Danser AH, Schalekamp MA, Bax WA, et al. (1995) Angiotensin converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92: 1387–1388
Data on file. Bosentan use in pediatrics. Actelion Pharmaceuticals, South San Francisco, CA
Data on file. Use in pediatrics. Pfizer Pharmaceuticals Group, Kalamazoo, MI
de Gasparo M, Levens N (1988) Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 82:257–271
Delyani JA, Myles K, Funder J (1998) Eplerenone (SC 66110), a highly selective aldosterone antagonist [Abstract]. Am J Hypertens 11:94A
Delyani JA, Robinson EL, Rudolph AE (2001) Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 281:H647–H654
Delyani JA, Rocha R, Cook CS, et al. (2001) Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 19:185–200
Deswal A, Bozkurt B, Seta Y, et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Entanercept) in patients with advanced heart failure. Circulation 99:3224–3226
Dieaguez-Lucena JL, Aranda-Lara P, Ruiz-Galdoh M, et al. (1996) Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension 28:98–103
Edes I, Gasior Z, Wita K (2005) Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 7:631–639
Edes I, Kiss E, Kitada Y et al. (1995) Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77:107–131
Edwards BS, Zimmerman RS, Schwab TR, et al. (1988) Atrial stretch, not pressure, is the prinicipal determinant controlling the release of atrial natriuretic factor. Circ Res 62:191–195
Ellis D, Moritz ML, Vats A, Janosky JE (2004) Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens 17:928–935
Eplerenone Package insert (2003) Pfizer Pharmaceuticals Group, Kalamazoo, MI
Etanercept (Enbrel). Data on File. Amgen Corporation, Seattle, WA
Etanercept (Enbrel) (2002) Package insert. Amgen Corporation, Seattle, WA
Exner DV, Dries DL, Domanski MJ, et al. (2001) Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344:1351–1357
Feingold B, Law YM (2004) Use of nesiritide in pediatric patients with congestive heart failure. J Heart Lung Transplant 23:1455–1459
Feldman AM, McTiernan C (2004) Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 4:11–19
Fichtischerer S, Rossig L, Breuer S, et al. (2001) Tumor necrosis factor antagonism with Etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104:3023–3025
Flather MD, Shibata MC, Coat AJ, et al. (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol an mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–252
Follath F, Cleland JGF, Just H, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LiDO study): a randomized double-blind trial. Lancet 360:196–202
Follath F, Franco F, Cardoso JS (2005) European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 96:80G–85G
Francis GS (1999) Is there still a future neutral endopeptidase inhibitors? Am Heart J 138:1007–1008
Garban HJ, Buga GM, Ignarro LJ (2004) Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanim of therapeutic vasorelaxation. J Cardiovasc Pharmacol 439:638–644
Gheorghiade M, Niazi I, Ouyang J (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107:2690–2696
Gheorghiade M, Orlandi C, Burnett JC, et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 11:260–269
Giardini A, Formigari R, Bronzetti G, et al. (2003) Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. Cardiol Young 13:333–336
Givertz MM, Colucci WS, LeJemtel TH, et al. (2000) Acute endothelin a receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101:2922–2927
Goldsmith SR, Francis GS, Cowley AW Jr (1986) Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58:295–299
Granger CB, McMurray JJ, Yusuf S, et al. (2003) CHARM Investigators and Committees. Effects of candesartan patients with chronic heart failure and preserved left-ventricularjejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781
Haikala H, Linden I-B (1995) Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1): S10–S19
Harjola V, Peuhkurinen K, Nieminen M, et al. (1999) Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 83:4(l)–8(l)
Heinemann A, Horina G, Stauber RE, et al. (1998) Lack of effect of a selective vasopressin V1a receptor anatagonist SR 49059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed. Br J Pharmacol 125:1120–1127
Hoch M, Netz H (2005) Heart failure in pediatric patients. Thorac Cardiovasc Surg 53(Suppl 2):S129–S134
Horenstein MS, Ross RD, Singh TP, Epstein ML (2002) Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. Pediatr Cardiol 23:100–102
Horiuchi M, Nishiyana H, Hama J, et al. (1993) Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 264:F286–F291
Hosenpud J, Levosimendan, (1999) a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 83:9(l)–11(l)
Infliximab (Remicade) Package insert (2003) Centocor, Malvern, PA
Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial (2002) J Am Med Assoc 287:1531–1540
Itoh H, Pratt RE, Dzau VJ (1990) Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86:1690–1697
Jain KK (2004) Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5:331–336
Janssen PM, Zeitz O, Hasenfuss G (1999) Transient and sustained impacts of hydroxy radicals on sarcoplasmic reticulum function: the protective effects of nebivolol. Eur J Pharmacol 366:223–232
Jong P, Demers C, McKelvie RS, Liu PP (2002) Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39:463–470
Kahn JC, Patey M, Dubois-Rande JL, et al. (1990) Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 335:118–119
Kaluski E, Kobrin I, Zimlichman R, et al. (2003) RITZ-5: randomized intravenous tezosentan (an endothelin A/B antagonist) for the treatmert of pulmonary edema. J Am Coll Cardiol 41:204–210
Kaye DM, Lefkovits J, Jennings GL, et al. (1995) Adverse consequences of high sympathetic nervous activity in the failing heart. J Am Coll Cardiol 26:1257–1263
Kearns GL (1995) Pharmacogenetics and development: are infants and increased risk for adverse outcomes? Curr Opin Pediatr 7:220–233
Kearns GL (2000) Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 106:S128–S138
Kim S, Ohta K, Hamaguchi A, et al. (1995) Angiotensin II type 1 receptor antagonist inhibits gene expression of transforming growth factor-ß1 and extracellular matrix in cardiac and vascular tissue of hypertensive rats. J Pharmacol Exp Ther 273:509–551
Kiowski W, Sutsch G, Hunziker P, et al. (1995) Evidence for endothelin-l-mediated vasoconstriction in severe chronic heart failure. Lancet 246:732–736
Kivikko M, Antila S, Eha J, et al. (2002) Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42:43–51
Kivikko M, Antila S,Eha J, et al. (2003) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40:465–471
Kivikko M, Lehtonen L, Colucci W, et al. (2003) Sustained hemodynamic effects of intravenous levosimendan. Circulation 107:81–86
Kleerekoper Q, Putkey JA (1999) Drug binding to cardiac troponin C. J Biol Chem 274:23932–23939
Koller KJ, Goeddel DV (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86:1081–1088
Kopustinskiene D, Pollesello P, Saris N (2001) Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 428:311–314
Kopustinskiene DM, Pollesello P, Saris NE (2004) Potassium-specific effecrs of levosimendan on heart mitochondria. Biochem Pharmacol 68:807–821
Kostrzewska A, Laudanski T, Steinwall M, et al. (1998) Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances. Acta Obstet Gynecol Scand 77:3–7
Laer S, Mir TS, Behn F, Eiselt M, et al. (1998) Carvedilol therapy in pediatric patients with congestive heari failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143:916–922
Law YM, Keller BB, Feingold BM, Boyle GJ (2005) Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 95:474–478
Leeder JS, Kearns GL (1997) Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 44:55–77
Lehtonen LA, Antila S, Pentikainen PJ (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43:187–203
Lepran I, Papp J (2003) Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats. Eur J Pharmacol 464:171–176
Levijoki J, Piero P, Kaivola J, et al. (2000) Further evidence for the cardiac troponin C mediated calcium sensitization by levosimedan: structure–response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 32:479–491
Levine B, Kalman H, Mayer L, et al. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 323:236–241
Lilleberg J, Antila S, Karlsson M, et al. (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 56:554–563
Lilleberg J, Nieminen S, Akkila J, et al. (1998) Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19:660–668
Liu JJ, Chen JR, Buxton BB, et al. (1995) Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin Via receptor antagonist, on human arterial coronary bypass graft. Clin Sci (Londn) 89:481–485
Loichot C, Cazaubon C, De Jong W, et al. (2000) Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmeidebergs Arch Pharmacol 361:319–326
Luscher TF, Enseleit F, Pacher R, et al. (2002) Hemodynamic and neurohormonal effects of selective endothelin A (ET A ) receptor blockade in chronic heart failure. Circulation 106:2666–2672
Luther YC, Schulze-Neick I, Stiller B, et al. (2004) Levosimendan–long-term inodilation in an infant with myocardial infarction. Z Kardiol 93:234–239
Maggioni AP, Anand I, Gottlieb SO, et al. Val-HeFT investigators (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40:1414–1421
Mahle WT, Cuadrado AR, Kirshborn PM, Kanter KR, Simsic JM (2005) Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 6:543– 546
Marcus LS, Hart D, Packer M, et al. (1996) Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 94:3184–3189
Marez D, Legrand M, Sabbagh N, et al. (1997) Ploymorphism of the cytochrome P450 CYP2D6 gene in a European papulation: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193–202
Marino MR, Vachharajani NN (2002) Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 40:112–122
Marshall J, Berkenbosch JW, Russo P, Tobias JD (2004) Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med 19:164–170
Martin J, Krum H (2001) Eplerenone (GD Searle & Co.). Curr Opin Invest Drugs 12:521–524
Materson BJ, Reda DJ, Cushman WC (1995) Department of Veterans Affairs single drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 8:189–192
McDowell G, Coutie W, Shaw C, et al. (1997) The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmgcol 43:329–332
!McKelvie RS, Yusuf S, Pericak D, et al; RESOLVD pilot study investigators (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100:1056–1064
McMurray JJ, Ostergren J, Swedberg K, CHARM et al. investigators and committee (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776
McNamara DM, Holubkov R, Janosko K, et al. (2001) Pharmacogenetic interactions between beta-blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103:1644–1648
Micromedex. Spironolactone—drug evaluation. Online healthcare series. (2003, October 12) Available at http://www. micromedex.com/products/hcsonline/
Mills RM, LeJemtel TH, Horton DP, et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. J Am Coll Cardiol 34:155–162
Mir TS, Marohn S, Laer S, et al. (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76
Moiseyev V, Poder P, Andrejevs N, et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422–1432
Mou S, Haudek S, Lequier L, et al. (2002) Myocardial inflammatory activation in children with congenital heart disease. Crit Care Med 30:827–832
National Institutes of Health Clinical Trials Web page, http://www.clinicaltrials.gov (accessed 2004, April 30)
Nieminen M, Akkila J, Hasenfuss G, et al. (2000) Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903–1912
Nijwahan N, Nicolosi A, Montgomery M, et al. (1999) Levosimendan enchances cardiac performance after cardio- pulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34:219–228
Northridge DB, Currie PF, Newby DE, et al. (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Failure 1:67–72
Northridge DB, Newby DE, Rooney E, et al. (1999) Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 138:1149–1157
Obayashi M, Yano M, Kohno M, et al. (1997) Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 273 (4 pt 2):H1824–H1831
O’Conner CM, Gattis WA, Adams KF, et al. (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes. Results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 41:1452–1457
O’Conner CM, Gattis WA, Gheorghiade M, et al. (1999) A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 138:1140–1148
Ooi H, Colucci WS, Givertz MM (2002) Endothelin mediates increased plumonary vascular tone in patients with failure. Circulation 106:1618–1621
Packer M, Colucci WS, Fisher L, et al. (2003) Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure: result with levosimendan in the REVIVE-1 study [Abstract]. J Card Failure 9:S61
Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG (2003) Functional channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17:115–121
Patterson JH, Rodgers JE (2003) Expanding role of beta-blockade in the management of chronic heart failure. Pharmacotherapy 23:451–459
Paulus WJ, Shah AM (1999) NO and cardiac diastolic function. Cardiovasc Res 43:595–606
Philipp S, Monti J, Pagel I, et al. (2002) Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure. Clin Sci 103:2495–2535
Pitt B, Poole-Wilson PA, Segal R, et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—The losartan heart failure survival study ELITE II. Lancet 355:1582–1587
Pitt B, Reicheck N, Willnebrock R, et al. (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation 108:1831–1838
Pitt B, Reichek N, Metscher B, et al. (2002) Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy [Abstract]. Am J Hypertens 15 (part 2):23A
Pitt B, Remme W, Zannad F, for the EPHESUS study group et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
Pitt B, Roniker B (1999) Eplerenone, a novel selective aldosterone receptor antagonist (SARA) dose finding study in patients with heart failure [Abstract]. J Am Coll Cardiol 33S188A–33S189A
Pitt B, Segal R, Martinez FA, et al. (1997) Randomised trial of losartan versus captopril in patients greater than 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349:747–752
Puddy VF, Amirmansour C, Williams AF, Singer DR (2002) Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (London) 103:75–77
Quashning L Ruschitzka F, Shaw S, et al. (2001) Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2 pt 2):801–805
Roberston WO (1998) Chemicals, children, and research $’s. Vet Hum Toxicol 40:308–309
Rocha R, Chander PN, Zuckerman A, et al. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33(1 pt 2) 232–237
Rocha R, Stier CT, Kifor I, et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871–3878
Rockman HA, Wachorst SP, Mao L, Ross J Jr (1994) ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 226(6 pt 2):H2468–H2475
Roniker B (1997) Eplerenone, a selective antagonist of the aldosterone receptor [Abstract]. Hypertension 30:995
Ross RD, Daniels SR, Schwartz DC, et al. (1987) Plasma norepinephrine levels in infants and childern with congestive heart failure. Am J Cardiol 59:911–914
Rouleau JU Pfeffer MA, Stewart DJ, et al. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 356:615–620
Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. (2004) Carvedilol in children with cardiomyopthy: 3-year experience at a single institution. J Heart Lung Transplant 23:832–838
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis randomized controlled trials. J Am Med Assoc 293:1900–1905
Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487–1491
Sakarcan A, Tenney F, Wilson JT, et al. (2001) The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 41:742–749
Sasaki M, Oki T, Iuchi A, et al. (1996) Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 14:1403–1408
Sato S, Hassan Talukder M, Sugawara H, et al. (1998) Effects of levosimendan on myocardial contractility and Ca++ transients in aequorin-loaded right ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30:1115–1128
Schalcher C, Cotter G, Reisin L, et al. (2001) The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142:340–349
Schulze-Neick I, Luther YC, Ewert P, et al. (2004) End stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart–lung transplantation. Transplantation 78:1237–1238
Scios, lnc. (2001) NDA 20-920: Natrecor (nesiritide) Cardiovascular and Renal Drugs Advisory Committee briefing document. Food and Drug Administration, Rockville, MD
Segarra G, Medina P, Vila JM, et al. (2002) Increased contraction to noradrenaline by vasopressin in human renal arteries. J Hypertension 20:1373–1379
Sehra R, Underwood K (2003) Nesiritide improves urine output in severely ill pediatric patients awaiting heart transplant without severe hypotension. J Card Failure 5:254
Serradeil Le-Gal G, Bourrie B, Raufaste D, et al. (1994) Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and mitogenic actiyity of vasopressin on Swiss 3T3 cells. Biochem Pharmacol 47:633–641
Serradeil Le-Gal C, Herbert JM, Delisse C, et al. (1995) Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am J Physiol 268(1 pt 2):H404–H410
Serradeil-Le Gal C, Villanova G, Boutin M, et al. (1995) Effects of SR 49059, a non-peptide antagonist of vasopressin-induced coronary vasoconstriction in conscious rabbits. Fundam Clin Pharmacol 9:17–24
Serradeil-Le Gal C, Wagnon J, Garcia C, et al. (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 92:224–231
Seymour AA, Swerdel JN, Abboa-Offei B (1991) Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 17:456–465
Shaddy R (2000) Beta-adrenergic blockers in the treatment of pediatric heart failure. Prog Pediatr Cardiol 12:113–118
Shaddy RE, Tani LY, Gidding SS, et al. (1999) Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 18:269–274
Shaddy RE (1998) Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 136:19–21
Shahinfar S, Cano F, Soffer BA, et al. (2005) A double-blind, dose–response study of losartan in hypertensive children. Am J Hypertens 18(2 pt 1):183–190
Silver MA, Horton DP, Ghali JK, et al. (2002) Effect of nesiritide versus dobutamine on short term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39:798–803
Simsic JM, Reddy VS, Kanter KR, Kirshbom PM, Forbess JM (2004) Use of nesiritide (human B-type natriuretic peptide) in infants following cardigc surgery. Pediatr Cardiol 25(6):668–670
Slawsky M, Colucci W, Gottlieb S, et al. (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102:2222–2227
Smith T, Rosen DA, Russo P, et al. (2005) Nesiritide during extracorporeal membrane oxygenation. Paediatr Anaesth 15:152–157
Smyth RL, Weindling AM (1999) Research in children: ethical and scientific aspects. Lancet 354(suppl 2):SII21–SII24
Solomon SD, Skali H, Bourgoun M, OVERTURE Investigators et al. (2005) Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 150:257–262
Speiker LE, Mitrovic V, Noll G, et al. (2000) Acute hemodynamic and neurohormonal effects of selective ET A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 35:1745–1752
Spieker LE, Noll G, Ruschitzka FT, Luscher TF (2001) Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 37:1493–1505
Suda K, Matsumura M, Matsumoto M (2003) Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45:249–254
Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new natriuretic pepetide in porcine brain. Nature 332:78–81
Sundberg S, Lehtonen L (2000) Haemodynamic interactions between the novel calcium sensitizer levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmool 55:793–799
Sutsch G, Bertel O, Kiowski W (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drug Ther 10:717–725
Sutsch G, Kiowski W, Yan XW, et al. (1998) Short term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98:2262–2268
Tahara A, Saito M, Sugimoto T, et al. (1998) Pharmacologic characterization of YM078, a potent, nonpeptide human vasopressin V1A and Vz recept or antagonist. Naunyn Schmeidebergs Arch Pharmacol 357:63–69
Tahara A, Saito M, Tsukada J, et al. (1999) Vasopressin increases vascular endothelial growth factor secretion from vascular smooth muscle cells. Eur J Pharmacol 368:89–94
Tahara A, Tomura Y, Wada K, et al. (1997) Effect of YM087, a potent non-peptide vasopressin antogonist on vasopressin-induced hyperplasia and hypertrophy of cultured smooth-muscle cells. J Cardiovasc Pharmacol 30:759–766
Tahara A, Tomura Y, Wada K, et al. (1997) Pharmacologic profile of YM087, a novel potent nonpeptide vasopressin VlA and V2 receptor antagonist, in vitro and vivo. J Pharmacol Exp Ther 282:301–308
Tahara A, Tomura Y, Wada K, et al. (1998) Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 38:198–205
Takahashi T, Yamaguchi E, Furya K, et al. (2001) The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Repir Med 95:130–135
Takeda T, Miyamori I Yoneda T, et al. (1995) Production of aldosterone in isolated rat blood vessels. Hypertension 25:170–173
akeda T, Miyamori I, Yoneda T, et al. (1996) Regulation of aldosterone synthase in human vascular endothelial cells by adrenocorticotropin. J Clin Endocrinol Metab 81:2797–2800
Tanaka H, Suzuki K, Nakahata T, et al. (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576–579
Tassani P, Schad H, Heimisch W, et al. (2002) Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetized pigs. Cardiovasc Drugs Ther 16:435–441
Taylor AL, (2005)The African American Heart Failure Trial: a clinical trial Update. Am J Cardiol 10:44–48
Teerlink JR, McMurray JJ, Bourge RC, VERITAS Investigators (2005) Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Study (VERITAS). Am Heart J 150:46–53
Thibonnier M, Kilani A, Rahmann M, et al. (1999) Effects of the nonpeptide Vl vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 341:1293–1300
Tomura Y, Tahara A, Tsukada, et al. (1999) Pharmacologic profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 26:399–403
Torre-Amione G (2002) A pilot safety trial of prolonged (48 hour) infusion of the dual endothelin receptor antagonist tezosentan in patients with advanced heart failure. Chest 120:460–466
Torre-Amione G, Kapadia S, Benedict C, et al. (1996) Proinflammatory cytokine levels in depressed left ventricular ejection fraction: a report from the studies of ventricular dysfunction (SOLVD). J Am Coll Card 27:1201–1206
Torre-Amione G, Young JB, Durand JB, et al. (2001) Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to class IV congestive heart failure. Circulation 103:973–980
Tsukada J, Tahara A, Tomura Y, et al. (2001) Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol 133:746–754
Tsukada J, Tahara A, Tomura Y, et al. (2002) Effects of YM471, an orally active non-peptide arginine vasopressin receptor antagonist of human vascular smooth muscle cells. J Hypertens 20:1807–1814
Tsukada J, Tahara A, Tomura Y, et al. (2002) Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist. Eur Pharmacol 446:129–138
Udleson JE, Smith WB, Hendrix GH, et al. (2001) Acute hemodynamic effects of conivaptan a dual VIA and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417–2423
Uhlir O, et al. (1994) Clinical and hemodynamic effects of nebivolol in patients with mild to moderate congestive heart failure. JRF Clinical Research Report NEB = TCH-4
Ukkonen H, Saraste M, Akkila J, et al. (2000) Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68:522–531
Ullian ME, Islam MM, Robinson CJ, et al. (1997) Resistance to mineralcorticoids in Wistr–Furth rats. Am J Physiol 272(3 pt 2): H1454–1461
Vachharajani NN, Shyu WC, Smith RA, Greene DS (1998) The effects of age and gender n the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46:611–613
Valjakka-Koskela R, Hirvonen J, Monkkonen J, et al. (2000) Transdermal delivery of levosimendan. Eur J Pharm Sci 11:343–350
Van Geel PP, Pinto YM, Voors AA, et al. (2000) Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 35:717–721
Van Kerckhoven R, Lankhuizen I, van Veghel R, et al. (2002) Chronic vasopressin V(la) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats. Eur J Pharmical 449:135–141
Vichiendilokkul A, Tran A, Racine E (2003) Nesiritide: A novel approach for acute heart failure. Ann Pharmacother 37:247–258
Virag L, Hala O, Marion A, et al. (1996) Cardiac electrophysiologic effects levosimendan, a new calcium sensitizer. Gen Pharmacol 27:551–556
Wada K, Tahara A, Arai Y, et al. (2002) Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 450:169–177
Wahlander H, Westerlind A, Lindstedt G, Lundberg PA, Holmgren D (2005) Increased levels of brain and atrial natriuretic peptides after the first palliative Operation, but not after a bidirectional Glenn anastomosis, in children with functionally univentricular hearts. Cardiol Young 13:268–274
Wang P, Ba ZF, Chaudry IH (1994) Administration of tumor necrosis factor alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266:H2535–H2541
Ward MR, Kanellakis P, Ramsey D, et al. (2001) Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467–472
Weber R, Pechere-Bertschi A, Hayoz D, et al. (1997) Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension 30:1121–1127
Westheim AS, Bostrom P, Christensen CC, et al. (1999) Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 34:l794–1801
White CT, Macpherson CF, Hurley RM, Matsell DG (2003) Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 18:1038–1043
Willienheimer R, Dahlof B, Rydberg E, Erhardt L (1999) AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 20:997–1008
Winkelmann BR (2004) American Heart Association scientific sessions. Expert Opin Invest Drugs 13:435–445
Winkelman BR, Russ AP, Nauck M, et al. (1999) Angiotensin M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 137:698–705
Wisenbaugh T, Katz T, Davis J, et al. (1993) Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 21:1094–1110
Wong W, Mauger D (2004) Treatment of Wilms tumor-related hypertension with losartan and captopril. Pediatr Nephrol 19:805–807
Yatsu T, Tomura Y, Tahara A, et al. (1999) Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 327:239–246
Yatsu T, Tomura Y, Tahara A, et al. (1997) Pharmacologic profile of YM087, a novel nonpeptide dual vasopressin V1 A and V2 receptor antagonist, in dogs. Eur J Pharmacol 321:225–230
Yatsu T, Tomura Y, Tahara A, et al. (1999) Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1 A/V2 receptor antagonist. Nippon Yakurigaku Zasshi 114 (Suppl): 1l3P–117P
Yatsu T, Kusayama T, Tomura Y, et al. (2002) Effect of conivaptan a combined vasopressin V1A and V2 receptor antagonist, on vasopressin-induced cardiac and hemodynamic changes in anaesthetized dogs. Pharmacol Res 46:375–381
Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333:249–259
Yue TL, Cheng HY, Lysko PG, et al. (1992) Carvedelol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J.Pharmacol Exp Ther 263:92–98
Yusuf S, Pfeffer MA, Swedberg K, et al. (2003) Comittees CHARM investigators and Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme Inhibitors: the CHARM-Added trial. Lancet 362:767–771
Zairis MN, Apostolatos C, Anatassiadis F, et al. (2004) Comparison of the effect of levosimendan or dobutamine or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) study. In: Program and abstracts of the European Society of Cardliology, Heart Failure Update 2004; June 12–15, Wroclaw Poland Abstract 273
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moffett, B.S., Chang, A.C. Future Pharmacologic Agents for Treatment of Heart Failure in Children. Pediatr Cardiol 27, 533–551 (2006). https://doi.org/10.1007/s00246-006-1289-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-006-1289-0